Telesta Therapeutics Inc  

(Public, TSE:TST)   Watch this stock  
Find more results for TSE:BNC
+0.005 (3.70%)
Oct 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.14 - 0.14
52 week 0.04 - 1.00
Open 0.14
Vol / Avg. 272,600.00/1.02M
Mkt cap 42.47M
P/E 19.75
Div/yield     -
EPS 0.01
Shares 303.37M
Beta -0.48
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin - 28.83%
Operating margin - 26.55%
EBITD margin - 49.15%
Return on average assets -40.04% 10.32%
Return on average equity -52.96% 22.92%
Employees 53 -
CDP Score - -


2600 Alfred-Nobel Blvd Suite 301
+1-514-6976636 (Phone)
+1-514-6977966 (Fax)

Website links


Telesta Therapeutics Inc. is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer. The Company owns a manufacturing facility for MCNA at Montreal, Quebec. The Company has not generated any revenues.

Officers and directors

James M. Rae Independent Chairman of the Board
Michael Joseph Berendt Ph.D. Chief Executive Officer, Chief Scientific Officer
Age: 67
Brian R. Ford Chief Financial Officer
Age: 67
Donald Olds Chief Operating Officer
Mohamed Elrafih Vice President - Manufacturing Operations
Yvon Bastien Independent Director
Age: 67
Lyne Fortin Independent Director
Gregory David Gubitz Independent Director